Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial.
Saved in:
| Title: | Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial. |
|---|---|
| Authors: | Leupe, Hannes1 (AUTHOR), Pauwels, Elin1 (AUTHOR), Vandamme, Timon2,3 (AUTHOR), Van den Broeck, Bliede4 (AUTHOR), Lybaert, Willem3 (AUTHOR), Dekervel, Jeroen5 (AUTHOR), Van Herpe, Filip5 (AUTHOR), Jaekers, Joris6 (AUTHOR), Cleeren, Frederik7 (AUTHOR), Hofland, Johannes8 (AUTHOR), Brouwers, Adrienne9 (AUTHOR), Koole, Michel1 (AUTHOR), Bormans, Guy7 (AUTHOR), Van Cutsem, Eric5 (AUTHOR), Geboes, Karen10 (AUTHOR), Laenen, Annouschka11 (AUTHOR), Verslype, Chris5 (AUTHOR), Stroobants, Sigrid12 (AUTHOR), Deroose, Christophe M.1 (AUTHOR) christophe.deroose@uzleuven.be |
| Source: | Journal of Neuroendocrinology. Aug2024, Vol. 36 Issue 8, p1-9. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 09538194 |
|---|---|
| DOI: | 10.1111/jne.13420 |
